Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> MutationsLecia V. Sequist, Martin Schüler, Sarayut Lucien Geater et al.|Journal of Clinical Oncology|2013Cited by 3.2k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih‐Hsin Yang, Lecia V. Sequist, Yi‐Long Wu et al.|The Lancet Oncology|2015Cited by 1.6k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialKeunchil Park, Luis Paz‐Ares, Eng-Huat Tan et al.|The Lancet Oncology|2016Cited by 1.2k